Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma

Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2019

At a glance

  • Drugs Toreforant (Primary)
  • Indications Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Aug 2018 Primary endpoint (Change from baseline in prebronchodilator forced expiratory volume in 1 second (preBD FEV1)) has not been met, according to results published in the Annals of Allergy, Asthma and Immunology.
    • 10 Aug 2018 Results published in the Annals of Allergy, Asthma and Immunology.
    • 30 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top